Clinical Efficacy and Mechanism of Weiwei Decoction in Intervening Precancerous Lesions of Gastric Cancer with Deficiency-Stasis-Turbidity Syndrome via Regulating Cancer-Associated Fibroblasts Based on the Toxin-Grime Theory
10.13359/j.cnki.gzxbtcm.2025.06.010
- VernacularTitle:基于"毒垢理论"探究萎胃汤调控癌相关成纤维细胞干预虚瘀夹浊型胃癌前病变的临床疗效及其机制
- Author:
Lun ZHANG
1
;
Yuwei LIU
;
Jianxing QIU
;
Jiamin CHEN
Author Information
1. 广东省第二中医院,广东 广州 510095;广州中医药大学第五临床医学院,广东 广州 510095
- Keywords:
toxin-grim theory;
Weiwei Decoction;
chronic atrophic gastritis;
precancerous lesions of gastric cancer(PLGC);
deficiency-stasis-turbidity syndrome;
cancer-associated fibroblasts(CAFs)
- From:
Journal of Guangzhou University of Traditional Chinese Medicine
2025;42(6):1364-1370
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy and mechanism of Weiwei Decoction in treating patients with precancerous lesions of gastric cancer(PLGC)differentiated as deficiency-stasis-turbidity syndrome.Methods From August 2021 to August 2023,a clinical observation was performed on 60 patients diagnosed as chronic atrophic gastritis accompanied by mild to moderate dysplasia and differentiated as deficiency-stasis-turbidity syndrome through traditional Chinese medicine(TCM)syndrome differentiation,electronic gastroscopy,and histopathological examination at the Department of Gastroenterology,Guangdong Second Traditional Chinese Medicine Hospital.The patients were randomly divided into a treatment group and a control group using a random number table,with 30 patients in each group.The control group was treated with oral use of Weifuchun Tablets,while the treatment group was given modified Weiwei Decoction according to syndrome differentiation.The treatment course lasted 24 weeks.Before and after treatment,the changes in TCM syndrome scores,gastroscopy and histopathological grading,and expression levels of markers of cancer-associated fibroblasts(CAFs)in gastric mucosal tissues of the two groups were observed.After treatment,the efficacy of TCM syndromes and medication safety were evaluated in both groups.Results(1)After 24 weeks of treatment,the total effective rate in the treatment group was 93.33%(28/30),and that in the control group was 63.33%(19/30).The TCM syndrome efficacy in the treatment group was significantly superior to that in the control group(P＜0.05).(2)After treatment,the TCM syndrome scores in both groups were significantly decreased compared to those before treatment(P＜0.01),and the decrease in the treatment group was significantly superior to that in the control group(P＜0.05).(3)After treatment,the histopathological grading of gastric mucosal atrophy,intestinal metaplasia,and dysplasia in the treatment group was significantly improved compared to that before treatment(P＜0.05),while no significant improvement was presented in the control group(P＞0.05).The improvement in histopathological grading of gastric mucosal atrophy,intestinal metaplasia,and dysplasia in the treatment group was significantly superior to that in the control group(P＜0.05 or P＜0.01).(4)After treatment,the expression levels of CAFs markers of fibroblast activation protein(FAP)and α-smooth muscle actin(α-SMA)in the treatment group were significantly decreased(P＜0.05),while the expression levels of FAP and α-SMA in the control group were significantly increased(P＜0.05)compared to those before treatment.The decrease in FAP and α-SMA expression levels of the treatment group was significantly greater than that of the control group(P＜0.01).(5)During the treatment period,no adverse drug events occurred in either group,indicating high safety.Conclusion Weiwei Decoction has significant therapeutic effect on PLGC patients with deficiency-stasis-turbidity syndrome.Its mechanism may be related to the down-regulation of FAP and α-SMA levels and inhibition of the expression of CAFs.
